GLP-1 receptor agonists semaglutide and tirzepatide demonstrate measurable improvements in exercise capacity, symptoms, and quality of life for patients with obesity-related heart failure with preserved ejection fraction (HFpEF). The therapies work through coordinated mechanisms including weight reduction, decreased inflammation, and improved cardiac congestion indices, with tirzepatide showing additional reductions in heart failure complications.
This finding addresses a critical gap in cardiovascular medicine. HFpEF represents roughly half of all heart failure cases and has historically lacked effective treatments beyond symptom management. The obesity-HFpEF connection creates a vicious cycle where metabolic dysfunction worsens cardiac performance. GLP-1 therapies break this cycle by targeting multiple pathways simultaneously—something traditional heart failure medications cannot achieve. However, this review reveals a crucial limitation: while these drugs improve morbidity markers, their impact on actual mortality remains unclear. Given that HFpEF patients often die from cardiovascular events rather than pump failure, demonstrating mortality benefits will be essential for widespread adoption. The phenotypically targeted approach represents a paradigm shift toward precision medicine in cardiology, but long-term mortality data will determine whether this promise translates into meaningful life extension.
